BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis

BCRP 驱动未接受化疗的乳腺癌脑转移产生内在化学耐药性

阅读:13
作者:Rebeca Uceda-Castro, Andreia S Margarido, Ji-Ying Song, Mark C de Gooijer, Hendrik A Messal, Cecilia R Chambers, Max Nobis, Ceren H Çitirikkaya, Kerstin Hahn, Danielle Seinstra, David Herrmann, Paul Timpson, Pieter Wesseling, Olaf van Tellingen, Claire Vennin, Jacco van Rheenen

Abstract

Although initially successful, treatments with chemotherapy often fail because of the recurrence of chemoresistant metastases. Since these tumors develop after treatment, resistance is generally thought to occur in response to chemotherapy. However, alternative mechanisms of intrinsic chemoresistance in the chemotherapy-naïve setting may exist but remain poorly understood. Here, we study drug-naïve murine breast cancer brain metastases (BCBMs) to identify how cancer cells growing in a secondary site can acquire intrinsic chemoresistance without cytotoxic agent exposure. We demonstrate that drug-naïve murine breast cancer cells that form cancer lesions in the brain undergo vascular mimicry and concomitantly express the adenosine 5'-triphosphate-binding cassette transporter breast cancer resistance protein (BCRP), a common marker of brain endothelial cells. We reveal that expression of BCRP by the BCBM tumor cells protects them against doxorubicin and topotecan. We conclude that BCRP overexpression can cause intrinsic chemoresistance in cancer cells growing in metastatic sites without prior chemotherapy exposure.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。